Accelerating Research That Can Revolutionize Cancer Care
Our integrated research centers (IRCs) are launchpads for novel immunotherapies, vaccines and technologies that have strong commercial potential. By bringing together top talent from multiple disciplines and applying principles of business development to medical research, we enable the efficient translation of scientific insights into real-world solutions.
Notable achievements emerging from these centers include clinical trials leading to the 2017 FDA approval of a new immunotherapy drug for Merkel cell carcinoma (a rare and usually deadly skin cancer) and breakthrough research that laid the groundwork for a vaccine to prevent HPV, which can lead to cervical cancer. Discoveries from our IRCs have led to the creation of numerous startup companies, including Juno Therapeutics and Adaptive Biotechnologies.